No Data Yet
Roivant Sciences increased its direct ownership in Immunovant to 64.65% after purchasing 16,666,666 shares for approximately $350 million on December 12, 2025.
Major insiders, including Roivant Sciences and GSK, invested over $550 million into biotech firms Immunovant, Kymera Therapeutics, and Wave Life Sciences following their recent secondary share offerings.
Immunovant is now prioritizing its next-generation antibody, IMVT-1402, for Graves' Disease, following a successful $550M capital raise. This strategic pivot sharpens the company's clinical focus and solidifies its financial runway through potential commercialization.